Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIMP3 | P35625 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | RECQL | P46063 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | BRCA1 | P38398 | 3/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | APEX1 | P27695 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | STAT1 | P42224 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903193 | 0.92 | TIMP3 (0.62) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL12410284 | 0.87 | TIMP3 (0.86) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL12410283 | 0.86 | TIMP3 (0.75) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL16921052 | 0.86 | TIMP3 (0.75) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL12903190 | 0.85 | TIMP3 (0.78) | TIMP3MEN1RECQLKMT2AMAPT | |
| SCHEMBL1902159 | 0.85 | TIMP3 (1.00) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL7234616 | 0.82 | FGF1 (0.62) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL17903022 | 0.80 | TIMP3 (0.48) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL21645072 | 0.78 | RECQL (0.86) | TIMP3MEN1RECQLKMT2AHSD17B10 | |
| SCHEMBL7230621 | 0.75 | CASP6 (0.60) | TIMP3MEN1KMT2ACYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | TIMP3 1272/4885MEN1 1619/4885RECQL 1591/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | TIMP3 863/4885MEN1 1414/4885RECQL 1232/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | TIMP3 2441/4885MEN1 1930/4885RECQL 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.